ClinicalTrials.gg
CompletedNCT07704021Updated Jul 15, 2026

Safety and Efficacy of EUS-guided Gallbladder Drainage Under Endoscopist-directed Conscious Sedation

An observational study in Cholecystitis, Acute, Pancreas Cancer, Duct Cell Adenocarcinoma and Cholangiocarcinoma, sponsored by Azienda Unita Sanitaria Locale di Piacenza. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Azienda Unita Sanitaria Locale di Piacenza · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
48
Ages
18 Years and older
Sex
All
01

Study summary

This prospective single-center study was designed by the investigators to evaluate the feasibility, safety, and efficacy of endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) performed under endoscopist-directed conscious sedation in elderly, high-risk patients with acute cholecystitis. The study aims to assess whether conscious sedation represents a viable alternative to deep sedation or general anesthesia in this fragile patient population.

Read the detailed description

Endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) has emerged as an effective minimally invasive treatment for acute cholecystitis in patients who are poor surgical candidates. Although the procedure is commonly performed under deep sedation or general anesthesia, many patients eligible for EUS-GBD are elderly and have significant comorbidities, making anesthesia management particularly challenging. Data regarding the use of endoscopist-directed conscious sedation for EUS-GBD remain limited.

The investigators designed this prospective single-center study to evaluate the feasibility, safety, and efficacy of EUS-GBD performed under endoscopist-directed conscious sedation in a cohort of elderly, high-risk patients with acute cholecystitis. The study focuses on procedural outcomes and sedation management, with particular attention to ketamine-based conscious sedation as a potential strategy for minimizing anesthesia-related risks in this vulnerable population.

02

Conditions studied

  • Cholecystitis, Acute
  • Pancreas Cancer, Duct Cell Adenocarcinoma
  • Cholangiocarcinoma

Keywords

  • gallbladder endoscopic ultrasound-guided drainage
  • sedation
  • acute cholecystitis
03

In context

Cholecystitis, Acute

140 studies on the registry are indexed under Cholecystitis, Acute; 30 are open to participants now.

This study's enrollment of 48 is below the median of 216 across 52 observational studies indexed under Cholecystitis, Acute.

Browse Cholecystitis, Acute studies →

Lead sponsor

Azienda Unita Sanitaria Locale di Piacenza is the lead sponsor of 15 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All consecutive patients undergoing EUS-GBD under conscious sedation at our tertiary referral center between January 2020 and October 2024 were prospectively enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • acute cholecystitis in patients considered unfit for surgery according to ASA Physical Status classification and clinical judgment.

Exclusion criteria

Exclusion Criteria:

  • age \<18 years
  • patients with acute cholecystitis fit for surgery
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
48 participants (actual)
Target follow-up
5 Years
Patient registry
Yes

Interventions

  • DrugSedation

    Performing endoscopic ultrasound-guided gallbladder drainage under endoscopist-directed conscious sedation.

    Also known as: endoscopic ultrasound- guided gallbladder drainage

06

What researchers measure

Primary outcomes

  1. Number of participants with sedation-related adverse events during EUS-guided gallbladder drainage

    Sedation-related adverse events occurring during or immediately after the procedure, including oxygen desaturation (SpO₂ \<90%), hypotension requiring intervention, bradycardia, need for airway support, unplanned conversion to deep sedation or general anesthesia, and procedure interruption due to sedation-related complications.

    Time frame: from April 2022 to April 2028

Secondary outcomes

  1. Number of participants with procedure-related adverse events

    Procedure-related adverse events occurring during or within 30 days after EUS-guided gallbladder drainage, classified according to the ASGE lexicon and graded by severity.

    Time frame: April 2022-2028

07

Study locations

1 site
  • Ospedale Guglielmo da Saliceto di Piacenza
    Piacenza, PC 29121, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07704021
Lead sponsor
Azienda Unita Sanitaria Locale di Piacenza
Responsible party
Anna Cominardi (Principal Investigator, Azienda Unita Sanitaria Locale di Piacenza) — Principal investigator
First posted
Jul 15, 2026
Start date
Apr 1, 2022
Primary completion
Apr 1, 2026
Completion
Jun 30, 2026
Last update
Jul 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion